Related Experiment Video
Updated: Apr 27, 2026
02:28
Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
1.1K
Patch test results in psoriasis patients on biologics
Noori Kim1, Shimrat Notik, Alice B Gottlieb
1From the Department of Dermatology, Tufts Medical Center, Boston, MA.
Dermatitis : Contact, Atopic, Occupational, Drug
|July 8, 2014
Summary
Biologic therapies for psoriasis do not appear to affect patch test results. This study found no significant difference in positive patch tests between psoriasis patients on biologics and those not on these treatments.
Area of Science:
- Dermatology
- Immunology
Background:
- Psoriasis is a chronic inflammatory skin condition.
- Biologic therapies target specific immune pathways for psoriasis treatment.
- Contact dermatitis is a common concern in dermatology.
Purpose of the Study:
- To investigate the prevalence of positive patch tests in psoriasis patients undergoing biologic therapy.
- To compare patch test reactivity in psoriasis patients on biologics versus those not on biologics.
Main Methods:
- Retrospective chart review of psoriasis patients who underwent patch testing between 2002 and 2012.
- Patients were categorized into groups based on current biologic use.
- Standardized North American Contact Dermatitis Group (NACDG) protocols were used for testing and grading reactions.
Main Results:
- No statistically significant differences were observed in the rates of positive patch tests (any reaction, 2+ reactions, or 3+ reactions) between patients on biologics and controls.
- Eighty percent of patients on biologics and 81% of controls had at least one positive patch test reaction.
- Rates of 2+ and 3+ reactions were similar between the two groups.
Conclusions:
- Biologic therapies do not seem to alter the ability of psoriasis patients to elicit a positive patch test response.
- Further research with larger patient cohorts is warranted to confirm these findings.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
872
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
872
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
745
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
745
01:24T Cell Types and Functions
3.2K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.2K
01:23Skin Diseases and Disorders
5.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.1K